



41
Docket No.: 102258.346

PATENT/OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

David S. GARVEY et al.

Serial No. 09/478,222

Filed: January 5, 2000

For: METHODS FOR TREATING HUMAN IMPOTENCE WITH NITRIC OXIDE DONOR COMPOUNDS

:
:
:
:
:
: Group Art Unit: 1639
:
: Examiner: Bennett M. Celsa

1639
RECEIVED
DEC 22 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

Copies of the documents listed on Form PTO-1449, some of which were cited in the prosecution of the corresponding PCT patent application, are enclosed. A copy of the search

12/18/2003 MGE BREM1 00000046 080219 09478222


01 FC:1806 180.00 DA

report for the PCT patent application is also enclosed.

The fee of \$180.00 pursuant to 37 CFR § 1.17(p) is attached. The Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 08-0219.

Respectfully submitted,

HALE AND DORR LLP



Edward D. Grieff
Registration No. 38,898

1455 Pennsylvania Avenue, NW
Washington, DC 20004

TEL 202.942.8400 EDG/srg

FAX 202.942.8484

Date: December 17, 2003

THIS PCT APPLICATION HAS NOT RECEIVED THE FOLLOWING:
PCT FEE (\$180.00) \$ 180.00

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

(PTO-1449)

ATTY. DOCKET NO.

102258.346

SERIAL NO.

09/478,222

APPLICANT

Garvey et al.

FILING DATE

January 5, 2000

GROUP

1639

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Pigini, M. et al. 1988. "Structure-Activity Relationships in 1, 4-Benzodioxan-Related Compounds. Investigation on the Role of the Dehydrodioxane Ring on alpha(1)-Adrenoreceptor Blocking Activity." *Journal of Medicinal Chemistry*. American Chemical Society, Washington. Vol. 31, No. 12, pp. 2300-2304.

Chenard, B.L. et al. October 1, 1991. "Separation of Alpha 1 Adrenergic and N-Methyl-D-Aspartate Antagonist activity in a Series of Ifenprodil Compounds." *Journal of Medicinal Chemistry*. American Chemical Society, Washington. Vol. 34, No. 10, pp. 3085-3090.

Zorgniotti, A.W. March 1, 1994. "Experience With Buccal Phentolamine Mesylate For Impotence." *International Journal of Impotence Research*. Vol. 6, No. 1, pp. 37-41

Wetzel, J.M. et al. May 12, 1995. "Discovery of Alpha 1A-Adrenergic Receptor Antagonists Based on the L-Type CA2+ Channel Antagonist Niguldipine." *Journal of Medicinal Chemistry*. American Chemical Society, Washington. Vol. 38, No. 10, pp. 1579-1581.

Regunathan, S et al. 1996. "Imidazoline Receptors and Their Endogenous Ligands." *Annual Review of Pharmacology and Toxicology*. Annual Review, Inc. Palo Alto, CA. Vol. 36, pp. 511-544.

Andersson, K.E. 2001. "Pharmacology of Penile Erection." *Pharmacological Reviews*. Vol. 53, No. 3, pp. 417-450.

Andersson, K.E. et al. 2001. "Oral Alpha Adrenoceptor Blockade as a Treatment of Erectile Dysfunction." *World J. Urol.* Vol. 19, pp. 9-13.

Tam, S.W. et al. 2001. "Yohimbine: A Clinical Review." *Pharmacology & Therapeutics*. Vol. 91, pp. 215-243.

June 6, 2002. European Search Report for European Application No. 97904887.3.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

(PTO-1449)

ATTY. DOCKET NO.

102258.346

SERIAL NO.

09/478,222

APPLICANT

Garvey et al.

FILING DATE

January 5, 2000

GROUP

1639

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	3,331,855	7/18/67	Popelak et al.			6/5/64
	3,574,212	4/6/71	Hess et al.			2/2/68
	3,940,387	2/24/76	Saint-Ruf et al.			5/5/72
	3,997,666	12/14/76	Witte et al.			1/28/75
	4,060,615	11/29/77	Matier et al.			2/18/76
	4,959,360	9/25/90	Lafferty et al.			6/6/89
	5,096,916	3/17/92	Skupin et al.			5/7/90
	5,236,904	8/17/93	Gerstenberg et al.			9/18/84
	5,380,758	1/10/95	Stamler et al.			9/14/92
	5,399,581	3/21/95	Laragh et al.			12/26/90
	5,403,847	4/4/95	Gluchowski et al.			11/13/92
	5,447,912	9/5/95	Gerstenberg et al.			8/16/93

RECEIVED
DEC 22 2003
TECH CENTER 160002600

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
	1249261	10/13/71	GB			X	
	1533529	11/29/78	GB			X	
	1548856	7/18/79	GB			X	
	9312068	6/24/93	WO			X	
	9505172	2/23/95	WO			X	
	9507075	3/16/95	WO			X	
	9632118	10/17/98	WO			X	

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	Urech, E. et al. 1950. "2-Aminoalkyl-imidazoline." <i>Helvetica Chimica Acta</i> . pp. 1386-1407.
	Dewar, G.H. et al. 1983. "Some Potential alpha-adrenoceptor blocking 1, 4-benzodioxanes and 2, 6-dimethoxyphenoxyethylamines." <i>Eur. J. Med. Chem. Chim. Ther.</i> Vol. 18, No. 3, pp. 286-290.
	Melchiorre, C. et al. 1984. "2-[[[2-(2,6-Dimethoxyphenoxy)ethyl]amino]-methyl]-1,4-benzoxathian: A New Antagonist With High Potency and Selectivity Toward alpha1-Adrenoreceptors." <i>J. Med. Chem.</i> Vol. 27, No. 12, pp. 1535-1536.
	Welbourn, A.P. et al. 1986. "Alpha-Adrenoceptor Reagents. 4. Resolutions of Some Potent Selective Prejunctional alpha2-adrenoceptor Antagonists." <i>J. Med. Chem.</i> Vol. 29, pp. 2000-2003
	Mitani, K. et al. 1988. "Novel Phenoxyalkylamine Derivatives. V. Synthesis, alpha-Blocking Activity and Quantitative Structure-Activity Analysis of alpha-(Phenoxyethylamino)propyl-1-alpha-phenylacetoneitrile Derivatives." <i>Chem. Pharm. Bull.</i> Vol. 36, No. 10, pp. 4121-4135.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.